Intra-operative cell salvage in cardiac surgery may increase platelet transfusion requirements

A cohort study

A. Z. Al-Riyami, M. Al-Khabori, B. Baskaran, M. Siddiqi, Hilal Al-Sabti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Objectives: The cell saver (CS) has been widely utilized in cardiac surgery to reduce red blood cell (RBC) transfusion. We aim at examining its effect on the rate of allogeneic transfusion, morbidity and mortality in our population. Materials and Methods: Retrospective review of all patients operated at the Sultan Qaboos University Hospital between 2008 and 2013 was performed. Patients' demographics, comorbidities and surgical details were retrieved. Study end-points included blood transfusion, infection, renal failure and mortality. Baseline characteristics of both groups were compared and differences were adjusted for in the multivariable logistic regression. Results: A total of 673 patients were included (CS = 395, non-CS = 278). Baseline characteristics were similar except for systemic hypertension, congestive heart failure and use of cardiopulmonary bypass. The CS group had higher transfusion rates of platelets (CS 36% vs. non-CS 18%; P <0·001) and plasma (CS 31% vs. non-CS 19%; P <0·001). After adjusting for baseline differences, CS use increased the odds of receiving platelet transfusion (odds ratio (OR) 3·2; P <0·001) but not of plasma transfusion (OR 1·6; P = 0·087). There was no difference in the rate of RBC transfusion (CS 45% vs. non-CS 40%; P = 0·212), renal failure (CS 11% vs. non-CS 6%; P = 0·139), infection (CS 16% vs. non-CS 13%; P = 0·434) and mortality (CS 5% vs. non-CS 2%; P = 0·146). Conclusion: The CS use increases platelet requirements and has no impact on the rate of RBC transfusion in our population. These findings warrant caution with generalized use and require larger studies to confirm its results.

Original languageEnglish
Pages (from-to)280-286
Number of pages7
JournalVox Sanguinis
Volume109
Issue number3
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Platelet Transfusion
Thoracic Surgery
Cohort Studies
Erythrocyte Transfusion
Renal Insufficiency
Mortality
Odds Ratio
Infection
Plasma Cells
Cardiopulmonary Bypass
Blood Transfusion
Population
Comorbidity
Blood Platelets
Heart Failure
Logistic Models
Demography
Hypertension
Morbidity

Keywords

  • Platelet transfusion
  • Transfusion strategy
  • Transfusion-surgery

ASJC Scopus subject areas

  • Hematology

Cite this

Intra-operative cell salvage in cardiac surgery may increase platelet transfusion requirements : A cohort study. / Al-Riyami, A. Z.; Al-Khabori, M.; Baskaran, B.; Siddiqi, M.; Al-Sabti, Hilal.

In: Vox Sanguinis, Vol. 109, No. 3, 01.10.2015, p. 280-286.

Research output: Contribution to journalArticle

@article{8c9a1421e05a4b6083e3efc9f568195c,
title = "Intra-operative cell salvage in cardiac surgery may increase platelet transfusion requirements: A cohort study",
abstract = "Background and Objectives: The cell saver (CS) has been widely utilized in cardiac surgery to reduce red blood cell (RBC) transfusion. We aim at examining its effect on the rate of allogeneic transfusion, morbidity and mortality in our population. Materials and Methods: Retrospective review of all patients operated at the Sultan Qaboos University Hospital between 2008 and 2013 was performed. Patients' demographics, comorbidities and surgical details were retrieved. Study end-points included blood transfusion, infection, renal failure and mortality. Baseline characteristics of both groups were compared and differences were adjusted for in the multivariable logistic regression. Results: A total of 673 patients were included (CS = 395, non-CS = 278). Baseline characteristics were similar except for systemic hypertension, congestive heart failure and use of cardiopulmonary bypass. The CS group had higher transfusion rates of platelets (CS 36{\%} vs. non-CS 18{\%}; P <0·001) and plasma (CS 31{\%} vs. non-CS 19{\%}; P <0·001). After adjusting for baseline differences, CS use increased the odds of receiving platelet transfusion (odds ratio (OR) 3·2; P <0·001) but not of plasma transfusion (OR 1·6; P = 0·087). There was no difference in the rate of RBC transfusion (CS 45{\%} vs. non-CS 40{\%}; P = 0·212), renal failure (CS 11{\%} vs. non-CS 6{\%}; P = 0·139), infection (CS 16{\%} vs. non-CS 13{\%}; P = 0·434) and mortality (CS 5{\%} vs. non-CS 2{\%}; P = 0·146). Conclusion: The CS use increases platelet requirements and has no impact on the rate of RBC transfusion in our population. These findings warrant caution with generalized use and require larger studies to confirm its results.",
keywords = "Platelet transfusion, Transfusion strategy, Transfusion-surgery",
author = "Al-Riyami, {A. Z.} and M. Al-Khabori and B. Baskaran and M. Siddiqi and Hilal Al-Sabti",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/vox.12280",
language = "English",
volume = "109",
pages = "280--286",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Intra-operative cell salvage in cardiac surgery may increase platelet transfusion requirements

T2 - A cohort study

AU - Al-Riyami, A. Z.

AU - Al-Khabori, M.

AU - Baskaran, B.

AU - Siddiqi, M.

AU - Al-Sabti, Hilal

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background and Objectives: The cell saver (CS) has been widely utilized in cardiac surgery to reduce red blood cell (RBC) transfusion. We aim at examining its effect on the rate of allogeneic transfusion, morbidity and mortality in our population. Materials and Methods: Retrospective review of all patients operated at the Sultan Qaboos University Hospital between 2008 and 2013 was performed. Patients' demographics, comorbidities and surgical details were retrieved. Study end-points included blood transfusion, infection, renal failure and mortality. Baseline characteristics of both groups were compared and differences were adjusted for in the multivariable logistic regression. Results: A total of 673 patients were included (CS = 395, non-CS = 278). Baseline characteristics were similar except for systemic hypertension, congestive heart failure and use of cardiopulmonary bypass. The CS group had higher transfusion rates of platelets (CS 36% vs. non-CS 18%; P <0·001) and plasma (CS 31% vs. non-CS 19%; P <0·001). After adjusting for baseline differences, CS use increased the odds of receiving platelet transfusion (odds ratio (OR) 3·2; P <0·001) but not of plasma transfusion (OR 1·6; P = 0·087). There was no difference in the rate of RBC transfusion (CS 45% vs. non-CS 40%; P = 0·212), renal failure (CS 11% vs. non-CS 6%; P = 0·139), infection (CS 16% vs. non-CS 13%; P = 0·434) and mortality (CS 5% vs. non-CS 2%; P = 0·146). Conclusion: The CS use increases platelet requirements and has no impact on the rate of RBC transfusion in our population. These findings warrant caution with generalized use and require larger studies to confirm its results.

AB - Background and Objectives: The cell saver (CS) has been widely utilized in cardiac surgery to reduce red blood cell (RBC) transfusion. We aim at examining its effect on the rate of allogeneic transfusion, morbidity and mortality in our population. Materials and Methods: Retrospective review of all patients operated at the Sultan Qaboos University Hospital between 2008 and 2013 was performed. Patients' demographics, comorbidities and surgical details were retrieved. Study end-points included blood transfusion, infection, renal failure and mortality. Baseline characteristics of both groups were compared and differences were adjusted for in the multivariable logistic regression. Results: A total of 673 patients were included (CS = 395, non-CS = 278). Baseline characteristics were similar except for systemic hypertension, congestive heart failure and use of cardiopulmonary bypass. The CS group had higher transfusion rates of platelets (CS 36% vs. non-CS 18%; P <0·001) and plasma (CS 31% vs. non-CS 19%; P <0·001). After adjusting for baseline differences, CS use increased the odds of receiving platelet transfusion (odds ratio (OR) 3·2; P <0·001) but not of plasma transfusion (OR 1·6; P = 0·087). There was no difference in the rate of RBC transfusion (CS 45% vs. non-CS 40%; P = 0·212), renal failure (CS 11% vs. non-CS 6%; P = 0·139), infection (CS 16% vs. non-CS 13%; P = 0·434) and mortality (CS 5% vs. non-CS 2%; P = 0·146). Conclusion: The CS use increases platelet requirements and has no impact on the rate of RBC transfusion in our population. These findings warrant caution with generalized use and require larger studies to confirm its results.

KW - Platelet transfusion

KW - Transfusion strategy

KW - Transfusion-surgery

UR - http://www.scopus.com/inward/record.url?scp=84941600783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941600783&partnerID=8YFLogxK

U2 - 10.1111/vox.12280

DO - 10.1111/vox.12280

M3 - Article

VL - 109

SP - 280

EP - 286

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 3

ER -